Wei Zhu

Cytosurge AG, founded in 2009, is a biotechnology company that manufactures and distributes cutting-edge solutions based on its patented FluidFM® technology. At the heart of this technology are the hollow FluidFM Probes – the Micropipette, Nanopipette, and the Nanosyringe – specifically designed to offer a wide range of unique applications for single-cell manipulation in biology research. Cytosurge's current systems compatible with FluidFM probes include the FluidFM ADD-ON for AFM systems and the standalone semi-automated FluidFM OMNIUM system. Cytosurge's vision is to unlock novel cures by translating next-generation genetic designs into living cells, contributing to human well-being through advancements in single-cell technologies. As the partner of choice for precision gene engineering cell line manufacturing, Cytosurge enables next-generation biologic production and cell and gene therapy treatments, empowering people to live longer and healthier lives. Cytosurge implements advanced genetically engineered cell lines that bring next-generation therapies to fruition, bridging the gap between genetic design tools and the manufacturing of high-precision gene-engineered cell lines. With a unique single-cell workflow and dynamic gene expression analytics, Cytosurge manufactures advanced gene-engineered cell lines, empowering next-generation treatments to benefit human well-being.